Reactivation of Latent Toxoplasmosis in a Schizophrenia Pa-tient: A Case Report
Schizophrenia is a serious mental disorder characterized by chronic relapsing episodes of psychosis. The disease is multifactorial, where infections, genetic vulnerability and environmental factors are involved in the development of the illness. Toxoplasma gondii is one of the parasites that has long been known associated with schizophrenia in many studies. To date, there is growing evidence of association between T. gondii infections and schizophrenia. Herein we report a rare case of reactivated toxoplasmosis in a schizophrenia individual. This patient was incidentally diagnosed with reactivated T. gondii infection. He denied any symptoms of toxoplasmosis but experienced a mild psychiatric auditory hallucination. Serology test for T. gondii immunoglobulin antibodies measured a high positive IgG titer (135.9 IU/ml) and negative for IgM. Interestingly, nested PCR exhibited a positive result for the type I strain of T. gondii dense granular (GRA) 7 gene (GRA7). This case highlights the detection of probable reactivation of toxoplasmosis in an immunocompetent schizophrenic patient without psychiatric treatment-resistant and remains asymptomatic for toxoplasmosis. Both serology and molecular tools have been a helpful aid in establishing the diagnosis. Nonetheless, early detection as in this case may aid the patient management in the future.
2. Sutterland AL, Fond G, Kuin A, et al. Be-yond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addic-tion: Systematic review and meta-analysis. Acta Psychiatr Scand. 2015; 132(3):161–79.
3. Brown A. Further evidence of infectious insults in the pathogenesis and pathophys-iology of schizophrenia. Am J Psychiatry. 2011; 168(8):764–6.
4. Emelia O, Amal RN, Ruzanna ZZ, et al. Seroprevalence of anti-Toxoplasma gondii IgG antibody in patients with schizophre-nia. Trop Biomed. 2012; 29(1):151–9.
5. Montoya JG, Boothroyd JC, Kovacs JA. Toxoplasma gondii. In: Mandell G, Bennett J, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infec-tious Diseases. 8th ed. Elsevier; 2014. p. 3122-3153.e7.
6. Torrey EF, Yolken RH. Toxoplasma gondii and Schizophrenia. Emerg Infect Dis. 2003; 9(11):1375–80.
7. Gohardehi S, Sharif M, Sarvi S, et al. The potential risk of toxoplasmosis for traffic accidents: A systematic review and meta-analysis. Exp Parasitol. 2018; 191:19–24.
8. Flegr J, Havlícek J, Kodym P, Malý M, Smahel Z. Increased risk of traffic acci-dents in subjects with latent toxoplasmo-sis: A retrospective case-control study. BMC Infect Dis. 2002; 2(11).
9. Luft BJ, Remington JS. Toxoplasmic en-cephalitis in AIDS. Clin Infect Dis. 1992; 15(2):211-22.
10. Israelski DM, Remington JS. Toxoplas-mosis in the non-AIDS immunocom-promised host. Curr Clin Top Infect Dis. 1993; 13:322–56.
11. Pinon JM, Foudrinier F, Mougeot G, et al. Evaluation of risk and diagnostic value of quantitative assays for anti- Toxoplasma gondii immunoglobulin A (IgA), IgE, and IgM and analytical study of specific IgG in immunodeficient patients. J Clin Microbiol. 1995; 33:878–84.
12. Arab-Mazar Z, Fallahi S, Koochaki A, Haghighi A, Seyyed Tabaei SJ. Immunodi-agnosis and molecular validation of Toxo-plasma gondii-recombinant dense granular (GRA) 7 protein for the detection of tox-oplasmosis in patients with cancer. Micro-biol Res. 2016; 183:53–9.
13. Webster JP, Kaushik M, Bristow GC, McConkey GA. Toxoplasma gondii infection, from predation to schizophrenia: Can an-imal behaviour help us understand human behaviour? J Exp Biol. 2013; 216(1):99–112.
14. Prandovszky E, Gaskell E, Martin H, Dubey JP, Webster JP, McConkey GA. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS One. 2011; 6(9):e23866.
15. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizo-phrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizo-phr Res. 2003; 62(3):237-244.
16. Goodwin D. G, Strobl J, Mitchell SM, Zajac AM, and Lindsay DS. Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. J Parasitol. 2008; 94(2): 555–557.
17. Goodwin D. G, Strobl J, and Lindsay DS. Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cul-tures. J Parasitol. 2011; 97(1):148-51.
18. Fond G, Macgregor A, Tamouza R, et al. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neu-rosci. 2014; 264(2):179–83.
|Issue||Vol 16 No 3 (2021)|
|Toxoplasmosis Schizophrenia Reactivated Serology|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|